Paper Details

  1. Home
  2. Paper Details

Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

Author: BassNathan M, BorteyEnoch, ForbesWilliam P, FrederickR Todd, MullenKevin D, PoordadFred F, SanyalArun J, SheikhMuhammad Y

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 3, open-label maintenance study assessed the safety and rate of hospitalization with long-term rifaximin use in patients with hepatic encephalopathy (HE). Rifaximin, a gut-selective oral antimicrobial agent, had previously shown efficacy in reducing HE recurrence and hospitalizations.
Paper Details　
Original Abstract of the Article :
Rifaximin is a gut-selective, oral antimicrobial agent shown to reduce the recurrence of overt hepatic encephalopathy (HE) and HE-related hospitalizations in a 6-month, randomized, controlled trial (RCT). We performed a phase 3, open-label maintenance study to assess the safety and rate of hospitali...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cgh.2013.12.021

データ提供：米国国立医学図書館（NLM）

Rifaximin: A Safe Haven in the Storm of Hepatic Encephalopathy

Hepatic encephalopathy (HE), a serious complication of liver disease, can be as unpredictable as a desert sandstorm. This study explores the potential of rifaximin, a gut-selective antimicrobial agent, to prevent the recurrence of HE, offering a beacon of hope for patients facing this life-threatening condition.

Rifaximin's Promise for Long-Term HE Management

The study demonstrates the safety and tolerability of rifaximin for long-term maintenance of remission from overt HE. It provides compelling evidence that rifaximin can effectively reduce the recurrence of HE and HE-related hospitalizations, offering patients a much-needed sense of stability and well-being in the face of this challenging condition.

Hope for the Future of HE Treatment

The study's findings, like a well-stocked oasis in a harsh desert, offer hope for individuals struggling with HE. Rifaximin's potential as a long-term maintenance treatment, like a reliable camel navigating a treacherous desert, provides a much-needed lifeline for these patients.

Dr.Camel's Conclusion

This study reminds us that even in the most challenging medical situations, like navigating a vast desert, there is hope for finding solutions. Rifaximin's potential to prevent HE recurrence offers a glimmer of optimism for patients and their families.

Date :
  1. Date Completed 2015-03-12
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

24365449

DOI: Digital Object Identifier

10.1016/j.cgh.2013.12.021

Related Literature

Article Analysis
・Side Effects of rifaximin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.